T50 Calciprotein Crystallization and the Decreased Role of Fetuin-A in Type 2 Diabetes

Aim: Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress...

Full description

Saved in:

Bibliographic Details
Published in	Journal of Atherosclerosis and Thrombosis Vol. 32; no. 6; pp. 763 - 774
Main Authors	Mori, Katsuhito, Nakatani, Shinya, Uedono, Hideki, Emoto, Masanori, Nagakura, Yu, Nagata, Yuki, Watanabe, Toshio, Shoji, Tetsuo, Imanishi, Yasuo, Fukumoto, Shinya, Morioka, Tomoaki
Format	Journal Article
Language	English
Published	Japan Japan Atherosclerosis Society 01.06.2025
Subjects	Aged alpha-2-HS-Glycoprotein - analysis alpha-2-HS-Glycoprotein - metabolism Biomarkers - blood Calcium - blood Case-Control Studies Cross-Sectional Studies Crystallization Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - metabolism Female Fetuin-A Humans Male Middle Aged Serum calcification propensity T50 Type 2 diabetes (T2D) Vascular Calcification - blood Vascular Calcification - etiology Serum calcification propensity Fetuin-A Type 2 diabetes (T2D) T50
Online Access	Get full text
ISSN	1340-3478 1880-3873 1880-3873
DOI	10.5551/jat.65351

Cover

Abstract	Aim: Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress. This study examined whether T2D affects T50 and the potential role of fetuin-A in the relationship between T2D and T50.Methods: This cross-sectional study included 101 individuals with T2D and 101 individuals without diabetes (controls). T50 and fetuin-A levels were measured using the established nephelometric method and an enzyme-linked immunosorbent assay, respectively.Results: Although fetuin-A levels were higher in the T2D group, T50 was not significantly different between the T2D and control groups. In multivariable-adjusted analyses of the total population, T50 was not independently associated with the presence of T2D, fasting plasma glucose, or HbA1c, whereas T50 was significantly associated with fetuin-A, phosphate, and calcium levels. The association between T50 and fetuin-A was modified by the presence of T2D. A subgroup analysis revealed that the positive association between T50 and fetuin-A was significant but smaller in the T2D group, and that the associations of T50 with serum phosphate and calcium were more evident in the T2D group. Additional analyses showed that T50/fetuin-A ratio was lower in the T2D group and that T50/fetuin-A ratio was inversely correlated with fasting glucose and HbA1c levels.Conclusions: T2D itself was not significantly associated with T50 but T2D modified the association between T50 and fetuin-A in favor of developing vascular calcification in T2D.
AbstractList	Aim: Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress. This study examined whether T2D affects T50 and the potential role of fetuin-A in the relationship between T2D and T50.Methods: This cross-sectional study included 101 individuals with T2D and 101 individuals without diabetes (controls). T50 and fetuin-A levels were measured using the established nephelometric method and an enzyme-linked immunosorbent assay, respectively.Results: Although fetuin-A levels were higher in the T2D group, T50 was not significantly different between the T2D and control groups. In multivariable-adjusted analyses of the total population, T50 was not independently associated with the presence of T2D, fasting plasma glucose, or HbA1c, whereas T50 was significantly associated with fetuin-A, phosphate, and calcium levels. The association between T50 and fetuin-A was modified by the presence of T2D. A subgroup analysis revealed that the positive association between T50 and fetuin-A was significant but smaller in the T2D group, and that the associations of T50 with serum phosphate and calcium were more evident in the T2D group. Additional analyses showed that T50/fetuin-A ratio was lower in the T2D group and that T50/fetuin-A ratio was inversely correlated with fasting glucose and HbA1c levels.Conclusions: T2D itself was not significantly associated with T50 but T2D modified the association between T50 and fetuin-A in favor of developing vascular calcification in T2D. Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress. This study examined whether T2D affects T50 and the potential role of fetuin-A in the relationship between T2D and T50.AIMPatients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress. This study examined whether T2D affects T50 and the potential role of fetuin-A in the relationship between T2D and T50.This cross-sectional study included 101 individuals with T2D and 101 individuals without diabetes (controls). T50 and fetuin-A levels were measured using the established nephelometric method and an enzyme-linked immunosorbent assay, respectively.METHODSThis cross-sectional study included 101 individuals with T2D and 101 individuals without diabetes (controls). T50 and fetuin-A levels were measured using the established nephelometric method and an enzyme-linked immunosorbent assay, respectively.Although fetuin-A levels were higher in the T2D group, T50 was not significantly different between the T2D and control groups. In multivariable-adjusted analyses of the total population, T50 was not independently associated with the presence of T2D, fasting plasma glucose, or HbA1c, whereas T50 was significantly associated with fetuin-A, phosphate, and calcium levels. The association between T50 and fetuin-A was modified by the presence of T2D. A subgroup analysis revealed that the positive association between T50 and fetuin-A was significant but smaller in the T2D group, and that the associations of T50 with serum phosphate and calcium were more evident in the T2D group. Additional analyses showed that T50/fetuin-A ratio was lower in the T2D group and that T50/fetuin-A ratio was inversely correlated with fasting glucose and HbA1c levels.RESULTSAlthough fetuin-A levels were higher in the T2D group, T50 was not significantly different between the T2D and control groups. In multivariable-adjusted analyses of the total population, T50 was not independently associated with the presence of T2D, fasting plasma glucose, or HbA1c, whereas T50 was significantly associated with fetuin-A, phosphate, and calcium levels. The association between T50 and fetuin-A was modified by the presence of T2D. A subgroup analysis revealed that the positive association between T50 and fetuin-A was significant but smaller in the T2D group, and that the associations of T50 with serum phosphate and calcium were more evident in the T2D group. Additional analyses showed that T50/fetuin-A ratio was lower in the T2D group and that T50/fetuin-A ratio was inversely correlated with fasting glucose and HbA1c levels.T2D itself was not significantly associated with T50 but T2D modified the association between T50 and fetuin-A in favor of developing vascular calcification in T2D.CONCLUSIONST2D itself was not significantly associated with T50 but T2D modified the association between T50 and fetuin-A in favor of developing vascular calcification in T2D. Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress. This study examined whether T2D affects T50 and the potential role of fetuin-A in the relationship between T2D and T50. This cross-sectional study included 101 individuals with T2D and 101 individuals without diabetes (controls). T50 and fetuin-A levels were measured using the established nephelometric method and an enzyme-linked immunosorbent assay, respectively. Although fetuin-A levels were higher in the T2D group, T50 was not significantly different between the T2D and control groups. In multivariable-adjusted analyses of the total population, T50 was not independently associated with the presence of T2D, fasting plasma glucose, or HbA1c, whereas T50 was significantly associated with fetuin-A, phosphate, and calcium levels. The association between T50 and fetuin-A was modified by the presence of T2D. A subgroup analysis revealed that the positive association between T50 and fetuin-A was significant but smaller in the T2D group, and that the associations of T50 with serum phosphate and calcium were more evident in the T2D group. Additional analyses showed that T50/fetuin-A ratio was lower in the T2D group and that T50/fetuin-A ratio was inversely correlated with fasting glucose and HbA1c levels. T2D itself was not significantly associated with T50 but T2D modified the association between T50 and fetuin-A in favor of developing vascular calcification in T2D.
ArticleNumber	65351
Author	Nagata, Yuki Mori, Katsuhito Fukumoto, Shinya Shoji, Tetsuo Morioka, Tomoaki Emoto, Masanori Imanishi, Yasuo Nagakura, Yu Nakatani, Shinya Uedono, Hideki Watanabe, Toshio
Author_xml	– sequence: 1 fullname: Mori, Katsuhito organization: Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Nakatani, Shinya organization: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Uedono, Hideki organization: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Emoto, Masanori organization: Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Nagakura, Yu organization: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Nagata, Yuki organization: Vascular Science Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Watanabe, Toshio organization: Department of Premier Preventive Medicine, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Shoji, Tetsuo organization: Vascular Science Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Imanishi, Yasuo organization: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Fukumoto, Shinya organization: Department of Premier Preventive Medicine, Osaka Metropolitan University Graduate School of Medicine – sequence: 1 fullname: Morioka, Tomoaki organization: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/39721707$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU1v1DAQhi1URD_gwB9APgJSij_i2DmhaksLUiUktHC1JvaEepV1FjtRCb8ed7fskct4JD_zvvY75-QkjhEJec3ZpVKKf9jAdNkoqfgzcsaNYZU0Wp6UXtalr7U5Jec5bxiTUinxgpzKVguumT4jP9aK0RUMLuzSOGGIdJWWPMEwhD8whTFSiJ5O90iv0SWEjJ5-GwekY09vcJpDrK5omVovO6SCXgfocML8kjzvYcj46um8IN9vPq1Xn6u7r7dfVld3lVNNO1UeeyGgYy0603kGpmdKs0bwzoFuoXPeG2d47UXfGc1q6Dn43pcRrOuWdfKCvD_oznEHy0N5tt2lsIW0WM7sYzi2hGP34RT47QEuX_01Y57sNmSHwwARxzlbyetWSdNoU9A3T-jcbdEfRf8FV4B3B8ClMeeE_X99bw9sUQoOhjEOIaLdjHOKJRyLv7UftwtYwYSyZUuCNZYVHaYbWYqua6W03Lt-PChtyop-4tET0hTcgHtPKWyzL4_exxt3D8lilH8BuFaqkg
Cites_doi	10.1371/journal.pone.0188695 10.1016/B978-0-12-394317-0.00010-8 10.1530/EJE-16-0517 10.2215/CJN.04720416 10.3389/fcvm.2022.771096 10.1136/bmjdrc-2020-002016 10.1016/S0272-6386(03)00905-3 10.2215/CJN.04710419 10.1016/S0303-7207(00)00237-9 10.1016/j.cellsig.2010.11.003 10.2337/dc21-S002 10.1016/j.ekir.2016.12.008 10.1016/j.jjcc.2015.10.005 10.1136/bmj.4.5893.643 10.2337/diacare.29.02.06.dc05-1484 10.1002/dmrr.315 10.1016/j.jsb.2020.107577 10.1681/ASN.2013060635 10.5551/jat.GL2022 10.1007/s11914-018-0418-z 10.1038/bmt.2012.244 10.1016/j.ekir.2020.06.022 10.1016/j.metabol.2009.10.005 10.5551/jat.GL2017 10.2337/dc17-0720 10.1038/s41440-019-0284-9 10.1016/j.atherosclerosis.2016.05.044 10.1038/s41598-017-18336-4 10.2337/diacare.24.2.335 10.1038/s41598-017-12859-6 10.2215/CJN.13921217 10.1161/ATVBAHA.120.314187 10.3390/toxins14090637 10.5551/jat.RV17045 10.3390/biomedicines8090337 10.1093/ndt/gfg414 10.1681/ASN.2014070670 10.2215/CJN.16601020 10.1159/000491025 10.1053/j.ajkd.2008.12.034 10.1093/ndt/gfi039 10.1016/j.surg.2019.05.094 10.1681/ASN.2012030240
ContentType	Journal Article
Copyright	This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
Copyright_xml	– notice: This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
CorporateAuthor	Vascular Science Center for Translational Research Department of Nephrology Osaka Metropolitan University Graduate School of Medicine Department of Premier Preventive Medicine Endocrinology and Molecular Medicine Department of Vascular Medicine Department of Metabolism
CorporateAuthor_xml	– name: Department of Metabolism – name: Department of Vascular Medicine – name: Vascular Science Center for Translational Research – name: Endocrinology and Molecular Medicine – name: Osaka Metropolitan University Graduate School of Medicine – name: Department of Premier Preventive Medicine – name: Department of Nephrology
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY
DOI	10.5551/jat.65351
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1880-3873
EndPage	774
ExternalDocumentID	10.5551/jat.65351 39721707 10_5551_jat_65351 ex7domya_2025_003206_010_0763_07744557307 article_jat_32_6_32_65351_article_char_en
Genre	Journal Article
GroupedDBID	--- .55 29J 2WC 53G 5GY 5VS AAFWJ ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK DU5 E3Z F5P GX1 HYE JMI JSF JSH KQ8 OK1 OVT P6G RJT RNS RPM RZJ TR2 X7M 3O- TKC AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY
ID	FETCH-LOGICAL-c569t-def22ab09ec8bd0a8f0570621bca79abcdd8c814d2fb8704af1adfd2abe4490b3
IEDL.DBID	UNPAY
ISSN	1340-3478 1880-3873
IngestDate	Sun Sep 07 11:20:03 EDT 2025 Fri Jul 11 11:40:52 EDT 2025 Mon Jul 21 05:44:33 EDT 2025 Wed Oct 01 05:55:03 EDT 2025 Sun Sep 07 07:20:30 EDT 2025 Wed Sep 03 06:30:18 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	false
IsScholarly	true
Issue	6
Keywords	Serum calcification propensity Fetuin-A Type 2 diabetes (T2D) T50
Language	English
License	https://creativecommons.org/licenses/by-nc-sa/4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c569t-def22ab09ec8bd0a8f0570621bca79abcdd8c814d2fb8704af1adfd2abe4490b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://proxy.k.utb.cz/login?url=https://doi.org/10.5551/jat.65351
PMID	39721707
PQID	3149538678
PQPubID	23479
PageCount	12
ParticipantIDs	unpaywall_primary_10_5551_jat_65351 proquest_miscellaneous_3149538678 pubmed_primary_39721707 crossref_primary_10_5551_jat_65351 medicalonline_journals_ex7domya_2025_003206_010_0763_07744557307 jstage_primary_article_jat_32_6_32_65351_article_char_en
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2025-Jun-01
PublicationDateYYYYMMDD	2025-06-01
PublicationDate_xml	– month: 06 year: 2025 text: 2025-Jun-01 day: 01
PublicationDecade	2020
PublicationPlace	Japan
PublicationPlace_xml	– name: Japan
PublicationTitle	Journal of Atherosclerosis and Thrombosis
PublicationTitleAlternate	JAT
PublicationYear	2025
Publisher	Japan Atherosclerosis Society
Publisher_xml	– name: Japan Atherosclerosis Society
References	25) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992 33) Bressendorff I, Hansen D, Schou M, Pasch A and Brandi L: The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol, 2018; 13: 1373-1380 24) Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M and Nishizawa Y: Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care, 2006; 29: 468 35) Kurstjenhypom S, de Baaij JH, Bouras H, Bindels RJ, Tack CJ and Hoenderop JG: Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. European journal of endocrinology / European Federation of Endocrine Societies, 2017; 176: 11-19 4) Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J and Jahnen-Dechent W: Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol, 2012; 23: 1744-1752 28) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A and Yanai H: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853 14) Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis S, Chertow GM, Parfrey P, Ma X and Floege J: Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin J Am Soc Nephrol, 2017; 12: 315-322 36) Arnaud P and Kalabay L: Alpha2-HS glycoprotein: a protein in search of a function. Diabetes/metabolism research and reviews, 2002; 18: 311-314 11) Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG and Pasch A: Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol, 2014; 25: 339-348 6) Pluquet M, Kamel S, Choukroun G, Liabeuf S and Laville SM: Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review. Toxins (Basel), 2022; 14: 637 27) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for E and Clinical Management of A: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984 7) Kuro-o M: Phosphate as a Pathogen of Arteriosclerosis and Aging. Journal of atherosclerosis and thrombosis, 2021; 28: 203-213 23) Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M and Nishizawa Y: Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism, 2010; 59: 873-878 30) Mori K, Emoto M and Inaba M: Fetuin-A and the cardiovascular system. Adv Clin Chem, 2012; 56: 175-195 18) Dahdal S, Devetzis V, Chalikias G, Tziakas D, Chizzolini C, Ribi C, Trendelenburg M, Eisenberger U, Hauser T, Pasch A, Huynh-Do U, Arampatzis S and Swiss Systemic Lupus Erythematosus Cohort Study G: Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. PLoS One, 2018; 13: e0188695 31) Goustin AS and Abou-Samra AB: The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal, 2011; 23: 980-990 32) Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS and Grunberger G: Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol, 2000; 164: 87-98 34) Bressendorff I, Hansen D, Schou M, Silver B, Pasch A, Bouchelouche P, Pedersen L, Rasmussen LM and Brandi L: Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney Int Rep, 2017; 2: 380-389 37) Bielesz B, Reiter T, Marculescu R, Gleiss A, Bojic M, Kieweg H and Cejka D: Calcification Propensity of Serum is Independent of Excretory Renal Function. Sci Rep, 2017; 7: 17941 13) Lorenz G, Steubl D, Kemmner S, Pasch A, Koch-Sembdner W, Pham D, Haller B, Bachmann Q, Mayer CC, Wassertheurer S, Angermann S, Lech M, Moog P, Bauer A, Heemann U and Schmaderer C: Worsening calcification propensity precedes all-cause and cardiovascular mortality in haemodialyzed patients. Sci Rep, 2017; 7: 13368 38) Kakajiwala A, Pasch A, Rogers R, Hoofnagle A, Meloni S, Furth SL, Leonard MB, Copelovitch L and Denburg MR: Serum Calcification Propensity in Children on Chronic Hemodialysis. Kidney Int Rep, 2020; 5: 1528-1531 40) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003; 42: S1-201 19) Kantauskaite M, Bolten K, Boschheidgen M, Schmidt C, Kolb T, Eckardt KU, Pasch A, Schimmöller L, Rump LC, Voelkl J and Stegbauer J: Serum Calcification Propensity and Calcification of the Abdominal Aorta in Patients With Primary Aldosteronism. Front Cardiovasc Med, 2022; 9: 771096 26) Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H and Hirawa N: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res, 2019; 42: 1235-1481 2) Echouffo-Tcheugui JB, Allison M, Kalyani RR, Sims M, Bertoni AG and Golden SH: Abdominal Aortic Calcification Among Individuals With and Without Diabetes: The Jackson Heart Study. Diabetes Care, 2017; 40: e106-e107 15) Bostom A, Pasch A, Madsen T, Roberts MB, Franceschini N, Steubl D, Garimella PS, Ix JH, Tuttle KR, Ivanova A, Shireman T, Gohh R, Merhi B, Jarolim P, Kusek JW, Pfeffer MA, Liu S and Eaton CB: Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. Am J Nephrol, 2018; 48: 21-31 44) Koubaity O, Mandry D, Nguyen-Thi PL, Bihain F, Nomine-Criqui C, Demarquet L, Croise-Laurent V and Brunaud L: Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery, 2020; 167: 149-154 29) Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant, 2013; 48: 452-458 16) Shoji T, Nakatani S, Kabata D, Mori K, Shintani A, Yoshida H, Takahashi K, Ota K, Fujii H, Ueda S, Nishi S, Nakatani T, Yoshiyama M, Goto K, Hamada T, Imanishi M, Ishimura E, Kagitani S, Kato Y, Kumeda Y, Maekawa K, Matsumura T, Nagayama H, Obi Y, Ohno Y, Sai Y, Sakurai M, Sasaki S, Shidara K, Shoji S, Tsujimoto Y, Yamakawa K, Yasuda H, Yodoi S, Inaba M and Emoto M: Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial. Clin J Am Soc Nephrol, 2021; 16: 599-612 21) Nakatani S, Mori K, Sonoda M, Nishide K, Uedono H, Tsuda A, Emoto M and Shoji T: Association between Serum Zinc and Calcification Propensity (T50) in Patients with Type 2 Diabetes Mellitus and In Vitro Effect of Exogenous Zinc on T50. Biomedicines, 2020; 8: 337 42) Kinugasa M, Mori S, Takaya T, Ito T, Tanaka H, Satomi-Kobayashi S, Fujiwara S, Nishii T, Kono AK, Okita Y and Hirata K: Serum phosphate is an independent predictor of the total aortic calcification volume in non-hemodialysis patients undergoing cardiovascular surgery. J Cardiol, 2016; 68: 308-315 5) Calciscon AG: T50 Calcification Propensity test is renamed the T50 Calciprotein Crystallization test (T50® test). News Letter from Calciscon, https: //calciscon.com/campaign/004/ (Accessed March 02, 2024); 2024 9) Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R and Pasch A: Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis, 2016; 251: 404-414 22) American Diabetes Association: 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care, 2021; 44: S15-S33 17) Eelderink C, Te Velde-Keyzer CA, Frenay AS, Vermeulen EA, Bachtler M, Aghagolzadeh P, van Dijk PR, Gansevoort RT, Vervloet MG, Hillebrands JL, Bakker SJL, van Goor H, Pasch A, de Borst MH and consortium N: Serum Calcification Propensity and the Risk of Cardiovascular and All-Cause Mortality in the General Population: The PREVEND Study. Arterioscler Thromb Vasc Biol, 2020; 40: 1942-1951 39) Payne RB, Little AJ, Williams RB and Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J, 1973; 4: 643-646 3) Schurgin S, Rich S and Mazzone T: Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care, 2001; 24: 335-338 20) Mencke R, van der Vaart A, Pasch A, Harms G, Waanders F, Bilo HJG, van Goor H, Hillebrands JL and van Dijk PR: Serum calcification propensity is associated 22 44 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 35 14 36 15 37 16 38 17 39 18 19 1 2 3 4 5 6 7 8 9 40 41 20 42 21 43
References_xml	– reference: 25) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992 – reference: 17) Eelderink C, Te Velde-Keyzer CA, Frenay AS, Vermeulen EA, Bachtler M, Aghagolzadeh P, van Dijk PR, Gansevoort RT, Vervloet MG, Hillebrands JL, Bakker SJL, van Goor H, Pasch A, de Borst MH and consortium N: Serum Calcification Propensity and the Risk of Cardiovascular and All-Cause Mortality in the General Population: The PREVEND Study. Arterioscler Thromb Vasc Biol, 2020; 40: 1942-1951 – reference: 7) Kuro-o M: Phosphate as a Pathogen of Arteriosclerosis and Aging. Journal of atherosclerosis and thrombosis, 2021; 28: 203-213 – reference: 27) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for E and Clinical Management of A: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984 – reference: 35) Kurstjenhypom S, de Baaij JH, Bouras H, Bindels RJ, Tack CJ and Hoenderop JG: Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. European journal of endocrinology / European Federation of Endocrine Societies, 2017; 176: 11-19 – reference: 14) Pasch A, Block GA, Bachtler M, Smith ER, Jahnen-Dechent W, Arampatzis S, Chertow GM, Parfrey P, Ma X and Floege J: Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clin J Am Soc Nephrol, 2017; 12: 315-322 – reference: 13) Lorenz G, Steubl D, Kemmner S, Pasch A, Koch-Sembdner W, Pham D, Haller B, Bachmann Q, Mayer CC, Wassertheurer S, Angermann S, Lech M, Moog P, Bauer A, Heemann U and Schmaderer C: Worsening calcification propensity precedes all-cause and cardiovascular mortality in haemodialyzed patients. Sci Rep, 2017; 7: 13368 – reference: 10) Bundy JD, Cai X, Mehta RC, Scialla JJ, de Boer IH, Hsu CY, Go AS, Dobre MA, Chen J, Rao PS, Leonard MB, Lash JP, Block GA, Townsend RR, Feldman HI, Smith ER, Pasch A, Isakova T and Investigators CS: Serum Calcification Propensity and Clinical Events in CKD. Clin J Am Soc Nephrol, 2019; 14: 1562-1571 – reference: 40) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003; 42: S1-201 – reference: 2) Echouffo-Tcheugui JB, Allison M, Kalyani RR, Sims M, Bertoni AG and Golden SH: Abdominal Aortic Calcification Among Individuals With and Without Diabetes: The Jackson Heart Study. Diabetes Care, 2017; 40: e106-e107 – reference: 38) Kakajiwala A, Pasch A, Rogers R, Hoofnagle A, Meloni S, Furth SL, Leonard MB, Copelovitch L and Denburg MR: Serum Calcification Propensity in Children on Chronic Hemodialysis. Kidney Int Rep, 2020; 5: 1528-1531 – reference: 3) Schurgin S, Rich S and Mazzone T: Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care, 2001; 24: 335-338 – reference: 4) Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J and Jahnen-Dechent W: Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol, 2012; 23: 1744-1752 – reference: 5) Calciscon AG: T50 Calcification Propensity test is renamed the T50 Calciprotein Crystallization test (T50® test). News Letter from Calciscon, https: //calciscon.com/campaign/004/ (Accessed March 02, 2024); 2024: – reference: 12) Keyzer CA, de Borst MH, van den Berg E, Jahnen-Dechent W, Arampatzis S, Farese S, Bergmann IP, Floege J, Navis G, Bakker SJ, van Goor H, Eisenberger U and Pasch A: Calcification Propensity and Survival among Renal Transplant Recipients. J Am Soc Nephrol, 2016; 27: 239-248 – reference: 20) Mencke R, van der Vaart A, Pasch A, Harms G, Waanders F, Bilo HJG, van Goor H, Hillebrands JL and van Dijk PR: Serum calcification propensity is associated with HbA1c in type 2 diabetes mellitus. BMJ Open Diabetes Res Care, 2021; 9: – reference: 30) Mori K, Emoto M and Inaba M: Fetuin-A and the cardiovascular system. Adv Clin Chem, 2012; 56: 175-195 – reference: 28) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A and Yanai H: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853 – reference: 18) Dahdal S, Devetzis V, Chalikias G, Tziakas D, Chizzolini C, Ribi C, Trendelenburg M, Eisenberger U, Hauser T, Pasch A, Huynh-Do U, Arampatzis S and Swiss Systemic Lupus Erythematosus Cohort Study G: Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. PLoS One, 2018; 13: e0188695 – reference: 43) London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B and Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant, 2003; 18: 1731-1740 – reference: 8) Jahnen-Dechent W, Buscher A, Koppert S, Heiss A, Kuro-o M and Smith ER: Mud in the blood: the role of protein-mineral complexes and extracellular vesicles in biomineralisation and calcification. J Struct Biol, 2020; 212: 107577 – reference: 21) Nakatani S, Mori K, Sonoda M, Nishide K, Uedono H, Tsuda A, Emoto M and Shoji T: Association between Serum Zinc and Calcification Propensity (T50) in Patients with Type 2 Diabetes Mellitus and In Vitro Effect of Exogenous Zinc on T50. Biomedicines, 2020; 8: 337 – reference: 1) Taniwaki H, Ishimura E, Tabata T, Tsujimoto Y, Shioi A, Shoji T, Inaba M, Inoue T and Nishizawa Y: Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant, 2005; 20: 2472-2478 – reference: 29) Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant, 2013; 48: 452-458 – reference: 41) Bendix EF, Johansen E, Ringgaard T, Wolder M and Starup-Linde J: Diabetes and Abdominal Aortic Calcification-a Systematic Review. Curr Osteoporos Rep, 2018; 16: 42-57 – reference: 31) Goustin AS and Abou-Samra AB: The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal, 2011; 23: 980-990 – reference: 23) Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M and Nishizawa Y: Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism, 2010; 59: 873-878 – reference: 34) Bressendorff I, Hansen D, Schou M, Silver B, Pasch A, Bouchelouche P, Pedersen L, Rasmussen LM and Brandi L: Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney Int Rep, 2017; 2: 380-389 – reference: 36) Arnaud P and Kalabay L: Alpha2-HS glycoprotein: a protein in search of a function. Diabetes/metabolism research and reviews, 2002; 18: 311-314 – reference: 37) Bielesz B, Reiter T, Marculescu R, Gleiss A, Bojic M, Kieweg H and Cejka D: Calcification Propensity of Serum is Independent of Excretory Renal Function. Sci Rep, 2017; 7: 17941 – reference: 44) Koubaity O, Mandry D, Nguyen-Thi PL, Bihain F, Nomine-Criqui C, Demarquet L, Croise-Laurent V and Brunaud L: Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery, 2020; 167: 149-154 – reference: 19) Kantauskaite M, Bolten K, Boschheidgen M, Schmidt C, Kolb T, Eckardt KU, Pasch A, Schimmöller L, Rump LC, Voelkl J and Stegbauer J: Serum Calcification Propensity and Calcification of the Abdominal Aorta in Patients With Primary Aldosteronism. Front Cardiovasc Med, 2022; 9: 771096 – reference: 16) Shoji T, Nakatani S, Kabata D, Mori K, Shintani A, Yoshida H, Takahashi K, Ota K, Fujii H, Ueda S, Nishi S, Nakatani T, Yoshiyama M, Goto K, Hamada T, Imanishi M, Ishimura E, Kagitani S, Kato Y, Kumeda Y, Maekawa K, Matsumura T, Nagayama H, Obi Y, Ohno Y, Sai Y, Sakurai M, Sasaki S, Shidara K, Shoji S, Tsujimoto Y, Yamakawa K, Yasuda H, Yodoi S, Inaba M and Emoto M: Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial. Clin J Am Soc Nephrol, 2021; 16: 599-612 – reference: 24) Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M and Nishizawa Y: Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care, 2006; 29: 468 – reference: 6) Pluquet M, Kamel S, Choukroun G, Liabeuf S and Laville SM: Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review. Toxins (Basel), 2022; 14: 637 – reference: 39) Payne RB, Little AJ, Williams RB and Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J, 1973; 4: 643-646 – reference: 11) Smith ER, Ford ML, Tomlinson LA, Bodenham E, McMahon LP, Farese S, Rajkumar C, Holt SG and Pasch A: Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol, 2014; 25: 339-348 – reference: 15) Bostom A, Pasch A, Madsen T, Roberts MB, Franceschini N, Steubl D, Garimella PS, Ix JH, Tuttle KR, Ivanova A, Shireman T, Gohh R, Merhi B, Jarolim P, Kusek JW, Pfeffer MA, Liu S and Eaton CB: Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. Am J Nephrol, 2018; 48: 21-31 – reference: 26) Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H and Hirawa N: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res, 2019; 42: 1235-1481 – reference: 33) Bressendorff I, Hansen D, Schou M, Pasch A and Brandi L: The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects with End Stage Kidney Disease: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol, 2018; 13: 1373-1380 – reference: 42) Kinugasa M, Mori S, Takaya T, Ito T, Tanaka H, Satomi-Kobayashi S, Fujiwara S, Nishii T, Kono AK, Okita Y and Hirata K: Serum phosphate is an independent predictor of the total aortic calcification volume in non-hemodialysis patients undergoing cardiovascular surgery. J Cardiol, 2016; 68: 308-315 – reference: 22) American Diabetes Association: 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care, 2021; 44: S15-S33 – reference: 32) Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS and Grunberger G: Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol, 2000; 164: 87-98 – reference: 9) Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R and Pasch A: Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis, 2016; 251: 404-414 – ident: 18 doi: 10.1371/journal.pone.0188695 – ident: 30 doi: 10.1016/B978-0-12-394317-0.00010-8 – ident: 35 doi: 10.1530/EJE-16-0517 – ident: 14 doi: 10.2215/CJN.04720416 – ident: 19 doi: 10.3389/fcvm.2022.771096 – ident: 20 doi: 10.1136/bmjdrc-2020-002016 – ident: 40 doi: 10.1016/S0272-6386(03)00905-3 – ident: 10 doi: 10.2215/CJN.04710419 – ident: 32 doi: 10.1016/S0303-7207(00)00237-9 – ident: 31 doi: 10.1016/j.cellsig.2010.11.003 – ident: 22 doi: 10.2337/dc21-S002 – ident: 34 doi: 10.1016/j.ekir.2016.12.008 – ident: 42 doi: 10.1016/j.jjcc.2015.10.005 – ident: 39 doi: 10.1136/bmj.4.5893.643 – ident: 24 doi: 10.2337/diacare.29.02.06.dc05-1484 – ident: 36 doi: 10.1002/dmrr.315 – ident: 8 doi: 10.1016/j.jsb.2020.107577 – ident: 11 doi: 10.1681/ASN.2013060635 – ident: 28 doi: 10.5551/jat.GL2022 – ident: 41 doi: 10.1007/s11914-018-0418-z – ident: 29 doi: 10.1038/bmt.2012.244 – ident: 38 doi: 10.1016/j.ekir.2020.06.022 – ident: 23 doi: 10.1016/j.metabol.2009.10.005 – ident: 27 doi: 10.5551/jat.GL2017 – ident: 2 doi: 10.2337/dc17-0720 – ident: 26 doi: 10.1038/s41440-019-0284-9 – ident: 9 doi: 10.1016/j.atherosclerosis.2016.05.044 – ident: 5 – ident: 37 doi: 10.1038/s41598-017-18336-4 – ident: 3 doi: 10.2337/diacare.24.2.335 – ident: 13 doi: 10.1038/s41598-017-12859-6 – ident: 33 doi: 10.2215/CJN.13921217 – ident: 17 doi: 10.1161/ATVBAHA.120.314187 – ident: 6 doi: 10.3390/toxins14090637 – ident: 7 doi: 10.5551/jat.RV17045 – ident: 21 doi: 10.3390/biomedicines8090337 – ident: 43 doi: 10.1093/ndt/gfg414 – ident: 12 doi: 10.1681/ASN.2014070670 – ident: 16 doi: 10.2215/CJN.16601020 – ident: 15 doi: 10.1159/000491025 – ident: 25 doi: 10.1053/j.ajkd.2008.12.034 – ident: 1 doi: 10.1093/ndt/gfi039 – ident: 44 doi: 10.1016/j.surg.2019.05.094 – ident: 4 doi: 10.1681/ASN.2012030240
SSID	ssj0033552 ssib002822083
Score	2.4230442
Snippet	Aim: Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it... Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases...
SourceID	unpaywall proquest pubmed crossref medicalonline jstage
SourceType	Open Access Repository Aggregation Database Index Database Publisher
StartPage	763
SubjectTerms	Aged alpha-2-HS-Glycoprotein - analysis alpha-2-HS-Glycoprotein - metabolism Biomarkers - blood Calcium - blood Case-Control Studies Cross-Sectional Studies Crystallization Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - metabolism Female Fetuin-A Humans Male Middle Aged Serum calcification propensity T50 Type 2 diabetes (T2D) Vascular Calcification - blood Vascular Calcification - etiology
Title	T50 Calciprotein Crystallization and the Decreased Role of Fetuin-A in Type 2 Diabetes
URI	https://www.jstage.jst.go.jp/article/jat/32/6/32_65351/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=ex7domya/2025/003206/010&name=0763-0774e https://www.ncbi.nlm.nih.gov/pubmed/39721707 https://www.proquest.com/docview/3149538678 https://doi.org/10.5551/jat.65351
UnpaywallVersion	publishedVersion
Volume	32
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
ispartofPNX	Journal of Atherosclerosis and Thrombosis, 2025/06/01, Vol.32(6), pp.763-774
journalDatabaseRights	– providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: KQ8 dateStart: 20160101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: KQ8 dateStart: 20020101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: KQ8 dateStart: 19940101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: DIK dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: GX1 dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: RPM dateStart: 20160101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rb9MwED-NDvEQ4v0Ij8mDfU1JnTiOv1EVyoS0CaEVlU-WHdtSR5ZMayIofz3nJC0rAsQXf7FP8ePu_LPu7heAA-e0Fc6ZMI65DzNyFwpj05Abpg0Xggvti5OPjtPDWfJhzuY7sL-uhbkUv2d4mb8-VfUwZbEvkt5NGcLtAezOjj-Ov7QPqQR9SNJ6W08r5nli4449aFt26865eoqwy9fT3zrrQiEdJcWfEOZNuN6U52r1TRXFpVtneudX7U6XbPJ12NR6mP_4jcrxnwu6C7d7zEnGnZLcgx1b3odrR31U_QF8PmERmagiX7SsDYuSTC5WOP2i6Is0iSoNQaRI3rYgc2kN-VQVllSOTG3dLMpwTFDKv2kJJX2SzfIhzKbvTiaHYf-_hTBnqahDYx2lSkfC5pk2kcocgrkopSOdKy6Uzo3J8myUGOo0mnmi3EgZZ1DEJomIdPwIBmVV2idAFItyzji3KfZR7TIrchcpFRkr8IUYB_ByfSLyvKPVkPgc8TskcYdku0MBZN1ZbYb01tQOialM28YP3fT4WjU0-ADebJ2u7C1zKe13bqqzlZIU0Z5nRqU-sQ-_HaGnxYYnCWPo9ngA-2uFkGhyPo6iSls1Sxm3SbkZXvMBPO40ZTPD2LMhcS_9aqM6f1_h0_8a9Qxu-Ml2CWrPYVBfNPYFQqFa78GV9_PRXm8SPwFRYgWW
linkProvider	Unpaywall
linkToUnpaywall	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED9NHYKhie9Bxoc84DUlTeI4fltVqCakTQitaDxZdmxLHVkyrYmg_PU7x2lZESBe_GKf4o-788-6u18A3lqrDLdWh0nCXJiR2ZBrk4VMU6UZ54wrV5x8fJIdzdKPZ_RsCw5WtTA34vcUL_N357IZZjRxRdLbGUW4PYDt2cmn8dfuIZWiD0k7b-toxRxPbOLZgzZlN-6cW-cIu1w9_e6FD4V4Soo_Icy7cKetLuXyuyzLG7fO9P6v2h2fbPJt2DZqWPz8jcrxnwt6APd6zEnGXkkewpapHsHt4z6q_hi-nNKITGRZzDvWhnlFJldLnH5Z9kWaRFaaIFIk7zuQuTCafK5LQ2pLpqZp51U4Jijl3rQkJn2SzeIJzKYfTidHYf-_hbCgGW9CbWwcSxVxU-RKRzK3COaiLB6pQjIuVaF1XuSjVMdWoZmn0o6kthpFTJrySCV7MKjqyjwDImlUMMqYybAvVjY3vLCRlJE2HF-ISQCvVyciLj2thsDniNshgTskuh0KIPdntR7SW1M3JIlF1jVu6LrH1aqhwQdwuHG6orfMhTA_mK4vllLEiPYcM2rsEvvw2xF6WmxYmlKKbo8FcLBSCIEm5-IosjJ1uxBJl5Sb4zUfwFOvKesZJo4NiTnpN2vV-fsK9_9r1HPYcZP1CWovYNBcteYlQqFGveqN4Ro1pgSl
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=T50+Calciprotein+Crystallization+and+the+Decreased+Role+of+Fetuin-A+in+Type+2+Diabetes&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Nagakura%2C+Yu&rft.au=Shoji%2C+Tetsuo&rft.au=Fukumoto%2C+Shinya&rft.au=Uedono%2C+Hideki&rft.date=2025-06-01&rft.issn=1340-3478&rft.eissn=1880-3873&rft.volume=32&rft.issue=6&rft.spage=763&rft.epage=774&rft_id=info:doi/10.5551%2Fjat.65351&rft.externalDBID=n%2Fa&rft.externalDocID=10_5551_jat_65351
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon